SITE008-0067

SITE008 (KOR) › SITE008-0067

SITE008-0067

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2025-11-18

enrolled

AEs

10

Serious

1

Dropout signal

–

Adverse events

10

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-11-27 (study day 185); relationship: not assessed

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-10-04 (study day 131); relationship: not assessed

moderate assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-09-30 (study day 127); relationship: not assessed

mild assessed

Grade 2 Hepatitis — outcome: RECOVERED/RESOLVED; onset 2022-09-15 (study day 112); relationship: not assessed

moderate assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-09-04 (study day 101); relationship: NOT RELATED

mild assessed

Grade 4 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-08-09 (study day 75); relationship: not assessed; serious criteria: life-threatening

severe serious assessed

Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-07-08 (study day 43); relationship: NOT RELATED

mild assessed

Grade 3 Pruritus — outcome: RECOVERED/RESOLVED; onset 2022-06-30 (study day 35); relationship: not assessed

severe assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-06-17 (study day 22); relationship: not assessed

mild assessed

Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-06-06 (study day 11); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.